AbbVie Clinical Trial Pipeline — 341 Active Studies

Phase 1: 77, Phase 2: 70, Phase 3: 101, Other: 93

AbbVie's clinical pipeline is anchored by two powerful commercial franchises: hematology/oncology (Imbruvica/ibrutinib, Venclexta/venetoclax) and immunology (Skyrizi/risankizumab, Rinvoq/upadacitinib) as Humira biosimilar competition has accelerated revenue transition. In hematology, Venclexta's BCL-2 inhibition platform is expanding into AML, MDS, and combinations beyond CLL/SLL. Imbruvica successor programs (zanubrutinib and next-gen BTK degraders) continue generating new trials. In immunology, Skyrizi (IL-23p19) and Rinvoq (JAK1) are rapidly gaining label expansions across psoriatic arthritis, IBD, Crohn's disease, and atopic dermatitis. AbbVie's 2020 Allergan acquisition added the aesthetics pipeline and Botox franchise.

• Hematology (BCL-2, BTK, AML)
• Immunology (IL-23, JAK1)
• Oncology combinations (venetoclax-based)
• IBD / GI inflammation
• Dermatology

• Venclexta (venetoclax) — BCL-2 inhibitor, CLL/AML
• Imbruvica (ibrutinib) — BTK inhibitor, B-cell malignancies
• Skyrizi (risankizumab) — IL-23p19, psoriasis/Crohn's/UC
• Rinvoq (upadacitinib) — JAK1 inhibitor, arthritis/IBD/atopic
• ABBV-CLS-484 — SIRPα/CD47 axis, solid tumors
• Teliso-V (telisotuzumab vedotin) — c-MET ADC, NSCLC

AbbVie's venetoclax combination trials are the most closely watched in hematology — any new BCL-2 combination registered by AbbVie (e.g., with hypomethylating agents, CDK inhibitors, or immunotherapy) signals new standard-of-care potential in AML or CLL. Companies developing competing hematology assets must monitor this pipeline.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to AbbVie's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: AbbVie may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.